| Aktie | Ticker | Breite | GCS | 2026/Q1 | 2025/Q4 | 2025/Q3 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | ||||
| 1.614.081.570 $ | +771.693.340 $ | +561,8 % | 12 | 1.394.029.350 $ | +932.155.550 $ | +130,9 % | 9 | 401.939.000 $ | +104.309.000 $ | +72,7 % | 4 | ||||
| Abivax S.A. | ABVX | → 0 | Schwach | 167.025.000 $ | -89.199.500 $ | -34,8 % | 1 | 256.224.500 $ | +171.324.500 $ | +201,8 % | 1 | 84.900.000 $ | +84.900.000 $ | 1 | |
| Revolution Medicines, Inc. | RVMD | → 0 | Schwach | 230.968.750 $ | +207.472.000 $ | +883,0 % | 1 | ||||||||
| INVESCO QQQ TRUST, SERIES 1 | QQQ | → 0 | 215.008.500 $ | +215.008.500 $ | 1 | ||||||||||
| BIOMARIN PHARMACEUTICAL INC | BMRN | → 0 | Stark | 201.951.750 $ | +23.661.750 $ | +13,3 % | 1 | 178.290.000 $ | +133.337.200 $ | +296,6 % | 1 | ||||
| Arcellx, Inc. | ACLX | → 0 | 190.710.000 $ | +88.085.000 $ | +85,8 % | 1 | 102.625.000 $ | -78.462.500 $ | -43,3 % | 1 | |||||
| Terns Pharmaceuticals, Inc. | TERN | → 0 | 181.800.000 $ | +181.800.000 $ | 1 | ||||||||||
| NEUROCRINE BIOSCIENCES INC | NBIX | → 0 | Neutral | 164.675.000 $ | +160.904.300 $ | +4.267,2 % | 1 | ||||||||
| ARROWHEAD PHARMACEUTICALS, INC. | ARWR | → 0 | Schwach | 142.642.500 $ | +82.891.500 $ | +138,7 % | 1 | ||||||||
| Enliven Therapeutics, Inc. | ELVN | → 0 | Neutral | 127.400.000 $ | +68.418.000 $ | +116,0 % | 1 | ||||||||
| Ascendis Pharma A/S | ASND | → 0 | 85.773.750 $ | +48.456.750 $ | +129,9 % | 1 | 119.286.000 $ | +84.766.000 $ | +245,6 % | 1 | |||||
| GLOBUS MEDICAL INC | GMED | → 0 | Schwach | 111.320.250 $ | +39.732.750 $ | +55,5 % | 1 | ||||||||
| REPLIGEN CORP | RGEN | → 0 | Schwach | 108.983.500 $ | +95.383.120 $ | +701,3 % | 1 | ||||||||
| Bicara Therapeutics Inc. | BCAX | → 0 | Neutral | 107.903.250 $ | +47.736.000 $ | +79,3 % | 1 | ||||||||
| Nurix Therapeutics, Inc. | NRIX | → 0 | Neutral | 100.750.000 $ | +11.780.700 $ | +13,2 % | 1 | 88.969.300 $ | +56.860.300 $ | +177,1 % | 1 | ||||
| Nuvalent, Inc. | NUVL | → 0 | 95.128.000 $ | +13.105.500 $ | +16,0 % | 1 | |||||||||
| Apogee Therapeutics, Inc. | APGE | → 0 | Schwach | 92.587.000 $ | +51.073.000 $ | +123,0 % | 1 | ||||||||
| ALCON INC | ALC | → 0 | Neutral | 87.085.050 $ | +5.124.050 $ | +6,3 % | 1 | ||||||||
| DEXCOM INC | DXCM | → 0 | Stark | 84.621.750 $ | +40.883.250 $ | +93,5 % | 1 | ||||||||
| Immunocore Holdings plc | IMCR | → 0 | Neutral | 83.421.070 $ | +63.115.720 $ | +310,8 % | 1 | ||||||||
| 1.614.081.570 $ | +771.693.340 $ | +561,8 % | 12 | 1.394.029.350 $ | +932.155.550 $ | +130,9 % | 9 | 401.939.000 $ | +104.309.000 $ | +72,7 % | 4 | ||||